# Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma

> **NCT00190424** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 80 (actual)

## Conditions studied

- Glioblastoma

## Interventions

- **DRUG:** CpG-ODN

## Key facts

- **NCT ID:** NCT00190424
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-09
- **Primary completion:** 2008-10
- **Final completion:** 2010-10
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2012-12-13


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00190424

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00190424, "Randomized Phase 2 With CpG-ODN in Malignant Glioblastoma". Retrieved via AI Analytics 2026-08-23 from https://api.ai-analytics.org/clinical/NCT00190424. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*